A randomized open-label, phase II study of lapatinib/capecitabine, lapatinib/vinorelbine, or lapatinib/gemcitabine in patients (pts) with ErbB2-amplified metastatic breast cancer (MBC) progressing after taxane treatment-GLICO-0801
Gomez, H. L., Neciosup, S. P., Neron do Nascimento, Y., Ismael, G., Barrios, C. H.
Published in Journal of clinical oncology (20.05.2010)
Published in Journal of clinical oncology (20.05.2010)
Get full text
Journal Article